Event details
As financial services audit committee requirements and expectations evolve in today’s dynamic environment, it is critical for audit committee members to be current on industry developments.
This webinar series provides a deep dive into the most pressing issues affecting financial institutions today, including financial reporting and accounting standards. Plus, our specialists offer practical knowledge and industry expertise.
Each session is recommended for up to 1.5 hours of CPE credit.
Who should attend
Audit committee members, CFOs, CEOs, chief risk officers, chief information officers, chief technology officers, chief information security officers, financial reporting executives, and equivalent personnel
Presenters
Led by Sydney Garmong and Mark Shannon, and moderated by financial services leaders, this series features a variety of Crowe financial services and audit committee specialists.
Contact information
For additional information, please contact Trina Tapo.
Thursday, July 9, 2026
Thursday, October 8, 2026
Missed an audit committee webinar or need a refresher? Watch on demand.
If you missed a session, you can watch our past quarterly webinars on demand.
Register now
Captcha is required.
FDIC and NCUA publish Q4 25 results, banking agencies focus on regulatory burden reduction, SEC and CFTC announce MOU on coordination, and more.
Important technology, policy, M&A, financial, and tax issues are converging on healthcare organizations this year. Read this article to learn more.
Watch this webinar recording to explore IPO readiness strategies, financial reporting risks, and market considerations for life sciences companies.
FDIC and NCUA publish Q4 25 results, banking agencies focus on regulatory burden reduction, SEC and CFTC announce MOU on coordination, and more.
Important technology, policy, M&A, financial, and tax issues are converging on healthcare organizations this year. Read this article to learn more.
Watch this webinar recording to explore IPO readiness strategies, financial reporting risks, and market considerations for life sciences companies.